8I7

Gemina Laboratories Ltd. (8I7)

Market Closed
12 Dec, 20:00
XFRA XFRA
0. 07
0
0%
- Market Cap
- P/E Ratio
0% Div Yield
250 Volume
0 Eps
0.07
Previous Close
Day Range
0.07 0.07
Year Range
0.07 0.76
Want to track 8I7 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 15 days

Summary

8I7 closed Friday higher at €0.07, an increase of 0% from Thursday's close, completing a monthly decrease of -18.54% or €0.02. Over the past 12 months, 8I7 stock lost -84.83%.
8I7 is not paying dividends to its shareholders.
The last earnings report, released on Sep 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Dec 29, 2025.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on CNSX (CAD).

8I7 Chart

Gemina Laboratories Ltd. (8I7) FAQ

What is the stock price today?

The current price is €0.07.

On which exchange is it traded?

Gemina Laboratories Ltd. is listed on CNSX.

What is its stock symbol?

The ticker symbol is 8I7.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Dec 29, 2025.

Has Gemina Laboratories Ltd. ever had a stock split?

No, there has never been a stock split.

Gemina Laboratories Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Brian Firth CEO
XFRA Exchange
CA3686501071 ISIN
CA Country
6 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Gemina Laboratories Ltd. is a biotechnology firm immersed in the innovation, research, and development of in-vitro diagnostics focusing primarily on the Canadian market. With a foundational commitment to improving diagnostic solutions, the company pioneers in crafting rapid and reliable testing kits for infectious diseases. Since its inception in 2017, with its headquarters nestled in Burnaby, Canada, Gemina Laboratories has embarked on a mission to revolutionize the landscape of diagnostic testing through cutting-edge research and development strategies. This commitment extends to the establishment of a robust product pipeline aimed at enhancing the diagnosis of infectious respiratory diseases, thereby contributing significantly to public health management and response.

Products and Services

  • Legio X (COVID-19 Rapid Antigen Test)

This innovatively designed testing kit is a hallmark of Gemina Laboratories’ dedication to fighting the global pandemic. Legio X utilizes the groundbreaking Gemina Surface Chemistry technology, aiming to deliver swift and accurate diagnosis of COVID-19 infections. This rapid antigen test stands as a testament to the company’s efforts in addressing the urgent need for accessible and reliable diagnostic tools amidst the health crisis.

  • LEGIO X (Influenza AB Multiplex Lateral Flow Test)

Expanding its arsenal of diagnostic solutions, Gemina Laboratories has developed the LEGIO X for the efficient detection of Influenza A and B strains. This multiplex lateral flow test is engineered to offer precise and quick influenza diagnostics, leveraging the same innovative technology that powers the company’s COVID-19 rapid test. The development of LEGIO X underscores Gemina’s commitment to broadening its impact on respiratory disease diagnosis through the application of advanced diagnostic technologies.

The company is also ardently working on expanding its product pipeline with a focus on diagnosing a variety of infectious respiratory diseases. These development efforts are grounded in Gemina Laboratories’ vision to lead in the commercialization of diagnostic solutions that address a wide spectrum of global health challenges, emphasizing its role in advancing public health safety and disease management.

Contact Information

Address: 3800 Westbrook Mall
Phone: 604-760-1997